Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Mohsen Heidari, Shirin Dashtbin, Arezoo Asadi, Parisa Asadollahi, Ali Khatib, Mohammad Amin Ebrahimi, Zahra Ghanbari, Atieh Darbandi, Roya Ghanavati & Reza Pakzad. (2024) Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis. Future Microbiology 19:5, pages 449-459.
Read now
Read now
João Paulo Telles, Juliette Cieslinski, Juliano Gasparetto & Felipe Francisco Tuon. (2019) Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis. Expert Review of Anti-infective Therapy 17:7, pages 501-510.
Read now
Read now
Sally Ager & Kate Gould. (2012) Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infection and Drug Resistance 5, pages 87-102.
Read now
Read now
Vicenç Falcó, Ana Sánchez, Albert Pahissa & Jordi Rello. (2011) Emerging drugs for pneumococcal pneumonia. Expert Opinion on Emerging Drugs 16:3, pages 459-477.
Read now
Read now
Eugenios I Metaxas & Matthew E Falagas. (2009) Update on the safety of linezolid. Expert Opinion on Drug Safety 8:4, pages 485-491.
Read now
Read now
David J Herrmann, William J Peppard, Nathan A Ledeboer, Melissa L Theesfeld, John A Weigelt & Bryan J Buechel. (2008) Linezolid for the treatment of drug-resistant infections. Expert Review of Anti-infective Therapy 6:6, pages 825-848.
Read now
Read now
Konstantinos Z Vardakas, Fotinie Ntziora & Matthew E Falagas. (2007) Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy 8:14, pages 2381-2400.
Read now
Read now
P. W. de Feiter, J. A. Jacobs, M. J. H. M. Jacobs, C. Vink & S. van der Geest. (2005) Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens. Scandinavian Journal of Infectious Diseases 37:3, pages 173-176.
Read now
Read now
Dennis L Stevens, Brian Dotter & Karl Madaras-Kelly. (2004) A review of linezolid: the first oxazolidinone antibiotic. Expert Review of Anti-infective Therapy 2:1, pages 51-59.
Read now
Read now
. (2004) News in Brief. Expert Review of Anti-infective Therapy 2:1, pages 5-8.
Read now
Read now
Articles from other publishers (48)
Matteo Bassetti, Daniele R. Giacobbe, Laura Magnasco, Alberto Fantin, Antonio Vena & Nadia Castaldo. (2024) Antibiotic Strategies for Severe Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine 45:02, pages 187-199.
Crossref
Crossref
Anu Patel, Sarah B. Doernberg, Travis Zack, Atul J. Butte & Kendra K. Radtke. (2024) Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes. Clinical Pharmacology & Therapeutics 115:4, pages 847-859.
Crossref
Crossref
Eliezer Zachary Nussbaum, Sophia Koo & Camille N Kotton. (2024) Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study. Clinical Infectious Diseases.
Crossref
Crossref
Matthew C. Phillips, Noah Wald-Dickler, Kusha Davar, Rachael Lee, Rachel Baden, Paul Holtom & Brad Spellberg. (2023) Choosing patients over placebos: oral transitional therapy vs. IV-only therapy for bacteraemia and infective endocarditis. Clinical Microbiology and Infection 29:9, pages 1126-1132.
Crossref
Crossref
Kusha Davar, Devin Clark, Robert M Centor, Fernando Dominguez, Bassam Ghanem, Rachael Lee, Todd C Lee, Emily G McDonald, Matthew C Phillips, Parham Sendi & Brad Spellberg. (2023) Can the Future of ID Escape the Inertial Dogma of Its Past? The Exemplars of Shorter Is Better and Oral Is the New IV. Open Forum Infectious Diseases 10:1.
Crossref
Crossref
Naveed Saleem, Francis Ryckaert, Timothy Arthur Chandos Snow, Giovanni Satta, Mervyn Singer & Nishkantha Arulkumaran. (2022) Mortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments. Clinical Microbiology and Infection 28:7, pages 936-945.
Crossref
Crossref
Noah Wald-Dickler, Paul D. Holtom, Matthew C. Phillips, Robert M. Centor, Rachael. A. Lee, Rachel Baden & Brad Spellberg. (2022) Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. The American Journal of Medicine 135:3, pages 369-379.e1.
Crossref
Crossref
Abhijit M. Bal. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
201
212
.
Brad Spellberg, Henry F. Chambers, Daniel M. Musher, Thomas L. Walsh & Arnold S. Bayer. (2020) Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis. JAMA Internal Medicine 180:5, pages 769.
Crossref
Crossref
Amar Safdar & Donald Armstrong. 2019. Principles and Practice of Transplant Infectious Diseases. Principles and Practice of Transplant Infectious Diseases
419
445
.
Jesse D Sutton, Sena Sayood & Emily S Spivak. (2018) Top Questions in Uncomplicated, Non–Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases 5:5.
Crossref
Crossref
Konstantinos Z. Vardakas, Kyriakos K. Trigkidis, Eleni Boukouvala & Matthew E. Falagas. (2016) Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 48:1, pages 1-10.
Crossref
Crossref
Sayoko Kinoshita, Kyoichi Wada, Sachi Matsuda, Takeshi Kuwahara, Haruki Sunami, Takuma Sato, Osamu Seguchi, Masanobu Yanase, Takeshi Nakatani & Mitsutaka Takada. (2016) Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan. Internal Medicine 55:7, pages 719-724.
Crossref
Crossref
Johannes Nemeth, Gabriela Oesch & Stefan P. Kuster. (2015) Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 70:2, pages 382-395.
Crossref
Crossref
Samuel Y. Ash & John V.L. Sheffield. (2013) Pneumococcus. Medical Clinics of North America 97:4, pages 647-666.
Crossref
Crossref
Jinjian Fu, Xiaohua Ye, Cha Chen & Sidong Chen. (2013) The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections. PLoS ONE 8:3, pages e58240.
Crossref
Crossref
Michael R. Barbachyn. 2012. Antibiotic Discovery and Development. Antibiotic Discovery and Development
271
299
.
R. Rivas, M. Barrera, L. González, V. Domínguez, R. Sánchez & M.M. Romero. (2011) Effectiveness and Use of Linezolid in Hospitalisation Wards. Farmacia Hospitalaria (English Edition) 35:6, pages 322-325.
Crossref
Crossref
R. Rivas, M. Barrera, L. González, V. Domínguez, R. Sánchez & M.M. Romero. (2011) Efectividad y uso del linezolid en planta de hospitalización. Farmacia Hospitalaria 35:6, pages 322-325.
Crossref
Crossref
Samuel Shelburne & Daniel M. Musher. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases
409
421
.
Brett H. HeintzJenana Halilovic. (2010) Clinical Experience with Linezolid at a Large Academic Medical Center: A Case Series and Review of the Literature. Hospital Pharmacy 45:12, pages 916-926.
Crossref
Crossref
Maria Saroglou, Stavros Tryfon, Georgios Ismailos, Ioannis Liapakis, Manolis Tzatzarakis, Aristidis Tsatsakis, Apostolos Papalois & Demosthenes Bouros. (2010) Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion. Journal of Inflammation 7:1.
Crossref
Crossref
M. Marian Ijzerman, Kenneth J. Tack & David B. Huang. (2010) Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae. Clinical Therapeutics 32:13, pages 2198-2206.
Crossref
Crossref
Michael PfallerBenjamin Howden. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
895
919
.
N. Bourgeois-Nicolaos & F. Doucet-Populaire. (2010) Oxazolidinones. EMC - Maladies infectieuses 7:2, pages 1-13.
Crossref
Crossref
E. Bouza. (2009) New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 15, pages 44-52.
Crossref
Crossref
Thomas M. File & Donald E. Low. (2009) Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia. Clinical Pulmonary Medicine 16:5, pages 243-251.
Crossref
Crossref
Drosos E. Karageorgopoulos & Matthew E. Falagas. (2009) New antibiotics: optimal use in current clinical practice. International Journal of Antimicrobial Agents 34, pages S55-S62.
Crossref
Crossref
Steven J. Brickner, Michael R. Barbachyn, Douglas K. Hutchinson & Peter R. Manninen. (2008) Linezolid (ZYVOX), the First Member of a Completely New Class of Antibacterial Agents for Treatment of Serious Gram-Positive Infections. Journal of Medicinal Chemistry 51:7, pages 1981-1990.
Crossref
Crossref
Matthew E Falagas & Konstantinos Z Vardakas. (2008) Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections. Drug Safety 31:9, pages 753-768.
Crossref
Crossref
Matthew E Falagas, Ilias I Siempos & Konstantinos Z Vardakas. (2008) Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. The Lancet Infectious Diseases 8:1, pages 53-66.
Crossref
Crossref
P.M. Olaechea Astigarraga, J. Garnacho Montero, S. Grau Cerrato, O. Rodríguez Colomo, M. Palomar Martínez, R. Zaragoza Crespo, P. Muñoz García-Paredes, E. Cerdá Cerdá & F. Álvarez Lerma. (2007) Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico. Medicina Intensiva 31:6, pages 294-317.
Crossref
Crossref
P.M. Olaechea Astigarraga, J. Garnacho Montero, S. Grau Cerrato, O. Rodríguez Colomo, M. Palomar Martínez, R. Zaragoza Crespo, P. Muñoz García-Paredes, E. Cerdá Cerdá & F. Álvarez Lerma. (2007) Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico. Enfermedades Infecciosas y Microbiología Clínica 25:7, pages 446-466.
Crossref
Crossref
Lionel A. Mandell, Richard G. Wunderink, Antonio Anzueto, John G. Bartlett, G. Douglas Campbell, Nathan C. Dean, Scott F. Dowell, Thomas M. FileJr.Jr., Daniel M. Musher, Michael S. Niederman, Antonio Torres & Cynthia G. Whitney. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 44:Supplement_2, pages S27-S72.
Crossref
Crossref
Isaac F. Mitropoulos, John C. Rotschafer & Keith A. Rodvold. (2007) Adverse events associated with the use of oral cephalosporins/cephems. Diagnostic Microbiology and Infectious Disease 57:3, pages S67-S76.
Crossref
Crossref
M. Tamm, T. Todisco, C. Feldman, J. Garbino, F. Blasi, P. Hogan, P.J. de Caprariis & I.M. Hoepelman. (2007) Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clinical Microbiology and Infection 13:2, pages 162-171.
Crossref
Crossref
P.M. Olaechea Astigarraga, J. Garnacho Montero, S. Grau Cerrato, O. Rodríguez Colomo, M. Palomar Martínez, R. Zaragoza Crespo, P. Muñoz García-Paredes, E. Cerdá Cerdá & F. Álvarez Lerma. (2007) Resumen de las recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico. Farmacia Hospitalaria 31:6, pages 353-369.
Crossref
Crossref
S.J. Brickner. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
673
698
.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
H. Dutronc, F. Bocquentin, T. Galpérine, S. Lafarie-Castet & M. Dupon. (2005) Le linézolide, premier antibiotique de la famille des oxazolidinones. Médecine et Maladies Infectieuses 35:9, pages 427-434.
Crossref
Crossref
Jesús Fortún, Pilar Martín-Dávila, Enrique Navas, Ma Jesús Pérez-Elías, Javier Cobo, Marta Tato, Elia Gómez-G. De la Pedrosa, Enrique Gómez-Mampaso & Santiago Moreno. (2005) Linezolid for the treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 56:1, pages 180-185.
Crossref
Crossref
Pierre-Yves Bochud, Marc Bonten, Oscar Marchetti & Thierry Calandra. (2004) Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Critical Care Medicine 32:Supplement, pages S495-S512.
Crossref
Crossref
Francesco Blasi, Paolo Tarsia, Roberto Cosentini & Vincenzo Valenti. (2004) Newer antibiotics for the treatment of respiratory tract infections. Current Opinion in Pulmonary Medicine 10:3, pages 189-196.
Crossref
Crossref
Lionel A. Mandell, John G. Bartlett, Scott F. Dowell, Thomas M. FileJr.Jr., Daniel M. Musher & Cynthia Whitney. (2003) Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clinical Infectious Diseases 37:11, pages 1405-1433.
Crossref
Crossref
William A Craig. (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infectious Disease Clinics of North America 17:3, pages 479-501.
Crossref
Crossref
William Craig & David Andes. 2003. Community-Acquired Respiratory Infections. Community-Acquired Respiratory Infections
145
153
.
Mario Cazzola, Alessandro Sanduzzi & Maria Gabriella Matera. (2003) Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. Pulmonary Pharmacology & Therapeutics 16:3, pages 131-145.
Crossref
Crossref
Dennis J Stalker & Gail L Jungbluth. (2003) Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial. Clinical Pharmacokinetics 42:13, pages 1129-1140.
Crossref
Crossref